


Claim Amendments:

1-48. (Cancelled)

49. (New) A pharmaceutical composition comprising a drug and a polyethylenimine polymer according to the following formula:



wherein α is between 0 to 90%;

β is between 0 to 100%;

γ is between 0 to 50%;

wherein $\alpha + \beta + \gamma = 100\%$; and

each Z group is independently hydrogen or a hydrophobic substituent, said hydrophobic substituent being a linear or branched, substituted or unsubstituted, or a cyclic group; and

Y is a hydrophilic substituent;

said drug being poorly soluble in aqueous solvents.

50. (New) The pharmaceutical composition according to claim 49, wherein the monomer units identified with α , β and γ form any arrangement in the polyethylenimine polymer.

51. (New) The pharmaceutical composition according to claim 49, wherein the arrangement of the α , β and γ units are random or in a block copolymer form.

52. (New) The pharmaceutical composition according to claim 51, wherein said α , β and γ units are in block copolymer form having the arrangement $\alpha\beta\gamma\alpha\beta\gamma\alpha\beta\gamma$.

53. (New) The pharmaceutical composition according to claim 49 further comprising a pharmaceutically acceptable carrier.

54. (New) The pharmaceutical composition according to claim 49, wherein the drug is selected from the group consisting of cyclosporine; steroids; drugs with multicyclic ring structures which lack polar groups and etoposide.

55. (New) The pharmaceutical composition according to claim 54, wherein the drug is a steroid selected from the group consisting of prednisolone, oestradiol and testosterone.

56. (New) The pharmaceutical composition according to claim 54 wherein the drug is paclitaxel.